Articles that mention Pfizer -BoardProspects

Pfizer

0 Comments Leave a Comment

1-15 of 42 1 2 3 »
1. Mentioned In 42 Articles
2. Ian Read to Retire as Executive Chairman of Pfizer’s Board of Directors; Chief Executive Officer Dr. Albert Bourla Named Chairman
  
  Explore valdostadailytimes.com Sep 27 2019 BoardMoves
  
  ...Following its regularly scheduled meeting, the Board of Directors of Pfizer Inc. (NYSE:PFE) today announced that Executive Chairman of the Board Ian C. Read has chosen to retire on December 31, 2019, and that i...
  Read Full Article
  
  Comment
  
  Mentions: Ian Read Albert Bourla Pfizer
3. Sen. Elizabeth Warren Calls on ex-FDA Chief Gottlieb to Resign from Pfizer’s Board, says it ‘smacks of corruption’
  
  Explore CNBC.com Jul 2 2019 BoardNews
  
  Sen. Elizabeth Warren on Tuesday called on the former head of the Food and Drug Administration, Scott Gottlieb, to resign from Pfizers board of directors, saying the appointment months after leaving the agency smacks of corruption. This kind of revolving door influence-peddling smacks of...
  Read Full Article
  
  Comment
  
  Mentions: Sen. Elizabeth Warren Pfizer Scott Gottlieb
4. Former FDA Commissioner Scott Gottlieb Joins Pfizer's Board of Directors
  
  Explore CNBC.com Jun 27 2019 BoardMoves
  
  ...its consumer healthcare business that it had been trying to sell. "We are fortunate to have Dr. Gottlieb join Pfizer's Board of Directors," Pfizer Executive Chairman and former CEO Ian Read said in a statement. "Scott's ...
  Read Full Article
  
  Comment
  
  Mentions: Pfizer Scott Gottlieb
5. AstraZeneca Plots Search for Next Chairman
  
  Explore Yahoo! UK & Ireland Finance Jun 3 2019 BoardNews
  
  ... company drew criticism for declining to link executive pay targets to the level at which the drug-maker said Pfizer had pitched an inadequate bid. AZ has continued to stoke investors' anger by paying Mr Soriot £11.4m la...
  Read Full Article
  
  Comment
  
  Mentions: Takeover Bid Succession CFO
6. Is CEO Pay Linked to Drug Prices? Curious Investors Failed Their Campaign to Find Out
  
  Explore Pharma News May 30 2019 BoardBlogs
  
  ...er earned $20.9 million. Vertex CEO Jeffrey Leiden snagged a pay raise to $18.8 million. Ahead of the vote, a Pfizer spokeswoman said the company "does not believe this proposal is in the best interests of the company or...
  Read Full Article
  
  Comment
  
  Mentions: Executive Compensation Investors Credit Suisse
7. Does Bristol-Myers Have a Plan B if Activists Scuttle its Celgene Buy?
  
  Explore Pharma News Mar 11 2019 BoardBlogs
  
  ...company could—and would—swallow a drugmaker of Bristol's size. Many of the best-equipped companies, including Pfizer and AbbVie, have come out against megadeals in recent weeks....
  Read Full Article
  
  Comment
  
  Mentions: Management Bristol-Myers Squibb risk
8. Mesa Labs Announces Changes in The Composition of Its Board of Directors
  
  Explore GlobeNewswire Mar 6 2019 BoardMoves
  
  ...elopment, Sales & Marketing, Technical Support and General Management. In her most recent experience, she led Pfizer’s Biosimilars business, growing global revenues from zero in 2015 to approximately $800 million today. ...
  Read Full Article
  
  Comment
  
  Mentions: Management CFO AMP
9. AstraZeneca Pays CEO Soriot Nearly $15M After 2018's Return to Growth. Will Investors Push Back?
  
  Explore Pharma News Mar 5 2019 BoardNews
  
  ...014 takeover attempt. Now, with AZ moving forward and launching promising new meds, he may be right about the Pfizer bid. Still, the company is still far short of its stated goal of $45 billion in sales by 2023, which So...
  Read Full Article
  
  Comment
  
  Mentions: Executive Compensation Investors stock options
10. Bristol-Myers Squibb has $2.2 Billion at Stake if its Deal to Acquire Celgene Falls Apart, and Opposition is Mounting
  
  Explore Business Insider Feb 28 2019 BoardNews
  
  ...trategy that will work. A lot is on the line: Including debt, the deal is the largest ever in pharma, topping Pfizer's 1999 acquisition of Warner-Lambert and last year's Takeda-Shire deal, according to Bloomberg News. If...
  Read Full Article
  
  Comment
  
  Mentions: Investment Management State Street
11. OMEICOS Therapeutics Strengthens Board of Directors with the Appointment of Christian Schetter
  
  Explore businesswire.com Feb 11 2019 BoardMoves
  
  ...h multiple financing rounds, a NASDAQ IPO and, following several significant pharma deals, to a trade sale to Pfizer in 2007. Before entering the life science industry, Christian was successfully performing academic rese...
  Read Full Article
  
  Comment
  
  Mentions: IPO Scripps California
12. Emergent BioSolutions Announces Appointment of Robert G. Kramer, Sr. to Its Board of Directors
  
  Explore GlobeNewswire Jan 24 2019 BoardMoves
  
  ...harmacia Corporation, which subsequently merged with the Upjohn Company in 1995 and eventually became part of Pfizer Inc. Mr. Kramer received an M.B.A. from Western Kentucky University and a B.S. in industrial management...
  Read Full Article
  
  Comment
  
  Mentions: Twitter CFO NYSE
13. Pharma Giant GlaxoSmithKline Signs Mega Deal With Pfizer That Could Change the Face of Global Healthcare
  
  Explore Business Insider Dec 19 2018 BoardNews
  
  ...rs and significant benefits to patients and consumers," said Emma Walmsley, chief executive of GSK. The Glaxo-Pfizer deal comes on a huge day for the pharmaceutical industry after Bloomberg reported that General Electric...
  Read Full Article
  
  Comment
  
  Mentions: IPO Sanofi stake
14. PhaseBio Appoints Edmund P. Harrigan to Board of Directors
  
  Explore P&T Community Dec 17 2018 BoardMoves
  
  ...hree decades of experience in the pharmaceutical industry to PhaseBio’s board. During his 18-year tenure with Pfizer, Dr. Harrigan held numerous leadership roles in business development, regulatory affairs and quality as...
  Read Full Article
  
  Comment
  
  Mentions: Nasdaq Edmund Harrigan PhaseBio
15. Activist Investor Elliott Has Taken Position in Germany's Bayer
  
  Explore SHARENET Dec 7 2018 BoardNews
  
  ...ues if they tried to buy the whole unit. Bayer ranks fifth in veterinary medicine, behind Zoetis , the former Pfizer unit, Elanco, formerly of Eli Lilly, unlisted Boehringer Ingelheim, which acquired animal health assets...
  Read Full Article
  
  Comment
  
  Mentions: Activist Investors Investors Sanofi
16. IASO BioMed Announces Addition of Four Members to Its Scientific Advisory Board
  
  Explore P&T Community Nov 13 2018 BoardMoves
  
  ... Mermelstein was the founder of Javelin Pharmaceuticals, Inc. (JAV), which was acquired by Hospira, Inc., now Pfizer. He has served as the CEO and President of Javelin, which has brought to market in Europe DylojectTM, a...
  Read Full Article
  
  Comment
  
  Mentions: Management Harvard Bloomberg
17. 1-15 of 42 1 2 3 »

Search:
Categories
1. BoardProspects Features:
  BoardBlogs, BoardKnowledge, BoardMoves, BoardNews, BoardProspects Announcements, BoardProspects CEO, CEO Blog, In the News, Partner Publications, Sponsored Content
Related Topics
1. Yahoo! Names Thompson CEO
  138 articles also mentioned Board of Directors
2. Shantanu Narayen Elected To Pfizer's Board Of Directors
  83 articles also mentioned CEO
3. Chrysler Adds Two to Board
  37 articles also mentioned AT&T
4. Molson Coors Adds Two to Board
  34 articles also mentioned Europe
5. Thompson Joins Microsoft Board
  32 articles also mentioned Johnson & Johnson
Quotes about Pfizer
1. We are pleased to welcome Shantanu Narayen to Pfizer's Board of Directors. He brings both leadership experience and a strong technology background to Pfizer's Board and will be an excellent asset to the company.
  Ian Read in Shantanu Narayen Elected To Pfizer's Board Of Directors
2. We are pleased to have Jim Smith join Pfizer's Board of Directors. He brings leadership and operational and international business experience to Pfizer's Board, and will be an excellent asset to the company.
  Ian Read in James C. Smith Elected to Pfizer’s Board of Directors
3. Amy is a recognized leader in the development and growth of global pharmaceutical businesses, and she will bring this expertise to our Board as we continue to build Alnylam as a leading biotechnology company. As the former General Counsel at Pfizer, Amy also brings deep legal expertise to our Board.
  In Alnylam Elects Amy Schulman to its Board of Directors

Mentioned In 42 Articles

Categories

BoardProspects Features:

Related Topics

Quotes about Pfizer